Syngenta announced it has acquired Novartis' repository of natural compounds and genetic strains for agricultural use, significantly boosting its research and development capabilities in the field.
The deal, set to close on June 1, includes the transfer of Novartis' Natural Products and Biomolecular Chemistry team to Syngenta. The company will also lease Novartis' fermentation pilot plant and science laboratories in Basel, Switzerland.
This acquisition follows Syngenta's recent opening of a biologicals production facility in Orangeburg, South Carolina, its first world-scale plant for agricultural biologicals in the U.S.
Camilla Corsi, Syngenta's Global Head of Crop Protection Research and Development, said, "The integration of these world-class assets opens a new chapter on our ability to develop cutting-edge biological solutions for farmers."
The move is part of Syngenta's broader strategy to accelerate biologicals innovation. Recent collaborations include partnerships with Provivi for pheromone solutions, Ginkgo Bioworks for innovative biologicals, and Intrinsyx Bio for nutrient use efficiency.
Jonathan Brown, Global Head of Syngenta's Seedcare and Biologicals business, emphasized the importance of maintaining innovation capacity in the growing biologicals market.
Biologicals, which include biocontrols, biostimulants, and nutrient use efficiency products, are crucial for supporting regenerative agriculture and sustainable farming practices. This expansion aligns with Syngenta's sustainability commitments and builds on its 2020 acquisition of Valagro, marking a continued focus on biological agricultural solutions.
